Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibitors of ftsz and uses thereof

a technology of inhibitors and antibacterial agents, applied in the field of antibacterial agents, can solve the problems of inability to understand the mechanism of action, the development of tolerance and/or resistance to antibacterial agents is a significant threat to the ability to treat disease, and the need for continual development of new agents

Inactive Publication Date: 2010-05-06
WHITE E LUCILE +2
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent describes a method for inhibiting bacterial growth, killing bacteria, and inhibiting the growth of bacteria by using certain compounds. These compounds can be administered to patients with bacterial infections to treat the infection. The technical effects of this invention include the ability to inhibit bacterial growth and kill bacteria, which can be useful in treating bacterial infections."

Problems solved by technology

However, in other cases the mechanisms of action are not understood.
The development of tolerance and / or resistance to anti-bacterial agents is a significant threat to the ability to treat disease.
As a result, continual development of new agents is required.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors of ftsz and uses thereof
  • Inhibitors of ftsz and uses thereof
  • Inhibitors of ftsz and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Anti-Tubercular Assay

[0162]Most anti-tubercular assays were conducted by the NIH Tuberculosis Anti-bacterial Acquisition and Coordination Facility (TAACF) screening facility against M. tuberculosis H37Rv (ATCC 27294; American Type Culture Collection, Manassas, Va.) using a BACTEC 460 radiometric system to determine the minimum inhibitory concentration (MIC99). Rifampin was the positive control. The MIC99 was also determined for SRI-7614 and SRI-3072 against strains of M. tuberculosis resistant to isoniazid, rifampin, ethambutol, kanamycin, pyrazinamide, thiacetazone, or cycloserine (Table 5). Concurrent with the determination of MIC99, compounds were tested for cytotoxicity (IC50) in Vero cells. After 72 h exposure, viability was assessed on the basis of cellular conversion of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) into a formazan product using the Promega CellTiter 96® AQueous Non-radioactive Cell Proliferation assay. The...

example 2

Purification and Characterization of FtsZ from M. tuberculosis

[0165]The purification of FtsZ was performed as described previously (White et al. J. Bact. 182:4028-4034, 2000). The M. tuberculosis FtsZ coding sequence was sub-cloned into the NcoI site of pET15b (Novagen). This plasmid, pJD168, was used to transform E. coli BL21 (DE3) / pLysS. Cells were incubated at 32° C. in LB media containing 0.4% glucose for 1 h. Five hundred μl of transformed cells were added to 250 ml of fresh LB media containing 0.4% glucose, 100 μg / ml ampicillin, and 34 μg / ml chloramphenicol and incubated overnight at 32° C. The cells were pelleted by centrifugation at room temperature. The cells were resuspended in four liters of prewarmed LB media containing 0.2% glucose, 100 μg / ml ampicillin, and 34 μg / ml chloramphenicol; the culture was shaken with good aeration at 32° C. When the culture reached an A600 of ˜0.4, expression of FtsZ was induced with 1 mM isopropyl β-D-thiogalactoside. Cells were harvested 3...

example 3

Light Scattering Assay for FtsZ Polymerization

[0170]The polymerization and depolymerization of purified FtsZ was followed by the method described by Mukherjee and Lutkenhaus for E. coli FtsZ (J. Bact. 181:823-832, 1999). Light scattering was measured in a thermostatically (30° C.) controlled Aminco-Bowman series 2 luminescence spectrometer using 0.5 ml quartz cuvets (cell 2×10 mm, Hellma). Excitation and emission wavelengths were 400 nm with a slit width of 2 nm. The gain was typically set at 540 V but was increased if needed to give a maximum response around 8. FtsZ (500 μg / ml; 13 μM) was incubated in 50 mM MES-NaOH pH 6.5, 100 mM KCl, and 5 mM MgCl2 to establish a baseline. GTP (40 μM) was added (final volume 300 μl) and the increase in light scattering measured for an additional 50-60 min. Changes in concentrations of a component for a particular experiment are indicated in the text or figure legend.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention relates to inhibitors of FtsZ polymerization and uses thereof.

Description

ACKNOWLEDGEMENTS[0001]This invention was made with government support under grant RO1 AI50470 awarded by the National Institutes of Health.FIELD OF THE INVENTION[0002]This invention generally relates to the field of anti-microbial agents and their uses, particularly inhibitors of FtsZ.BACKGROUND ART[0003]The mechanisms of action of many anti-bacterial agents have been well documented. For example, the mechanism of action of penicillin and other β-lactam drugs in inhibiting bacterial cell wall synthesis has been well studied. However, in other cases the mechanisms of action are not understood. There are six generic categories of action for anti-bacterial compounds, including inhibition of: 1) cell wall synthesis; 2) cell division; 3) cell membrane function; 4) protein synthesis; 5) nucleic acid synthesis; and 6) intermediary metabolism.[0004]The development of tolerance and / or resistance to anti-bacterial agents is a significant threat to the ability to treat disease. Many factors ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4985A61K31/551A61K31/437A61K31/44A61K31/542A61K31/5383A01N43/90A61P31/04A01N47/18A61K31/4409C07D213/75C07D405/12C07D471/04C07D471/14C07D471/16C07D498/04C07D513/04C07K14/35
CPCA01N47/18C07K14/35A61K31/44A61K31/495A61K31/498A61K31/505A61K31/506A61K31/525A61K31/535A61K31/54A61K31/55A61K31/5513C07D213/75C07D405/12C07D471/04C07D471/14C07D513/04A61K31/435A61P31/04Y02A50/30
Inventor WHITE, E. LUCILEREYNOLDS, ROBERT C.SULING, WILLIAM J.
Owner WHITE E LUCILE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com